Evidence map›Paper›PMID 38891846›Full record

ArticleInternational journal of molecular sciences2024

Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer.

Clara Meier, Gianluca La Rocca, Virginia Nawrot, Beate Fißlthaler, Sarah J Overby, Kai Hourfar, Guido Plotz, Christian Seidl, Paul Ziegler, Peter Wild and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Clara MeierBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Gianluca La RoccaBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Virginia NawrotBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Beate FißlthalerCentre for Molecular Medicine, Institute for Vascular Signalling, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Sarah J OverbyBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.ORCID 0000-0001-8195-9456
Kai HourfarGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute for Transfusion Medicine and Immunohematology, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Guido PlotzBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Christian SeidlGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute for Transfusion Medicine and Immunohematology, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Paul ZieglerDr. Senckenberg Institute of Pathology, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.ORCID 0000-0002-7703-7747
Peter WildDr. Senckenberg Institute of Pathology, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Stefan ZeuzemBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Jürgen BriegerDepartment of Otorhinolaryngology, University Medical Center Mainz, 55131 Mainz, Germany.
Elke JägerDepartment of Oncology and Hematology, Hospital Nordwest, 60488 Frankfurt, Germany.
Achim BattmannDepartment of Pathology, Hospital Nordwest, 60488 Frankfurt, Germany.
Angela BriegerBiomedical Research Laboratory, Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt, Germany.ORCID 0000-0003-1089-9710

Funding

Harry und Peter Fuld-FoundationInstitutional funds of the University Clinic Frankfurt
6 · The paper itself

Abstract

Tumor recurrence and drug resistance are responsible for poor prognosis in colorectal cancer (CRC). DNA mismatch repair (MMR) deficiency or elevated interleukin-8 (IL-8) levels are characteristics of CRCs, which have been independently correlated with treatment resistance to common therapies. We recently demonstrated significantly impaired therapeutical response and increased IL-8 release of CRC cell lines with reduced expression of MMR protein MLH1 as well as cytoskeletal non-erythrocytic spectrin alpha II (SPTAN1). In the present study, decreased intratumoral MLH1 and SPTAN1 expression in CRCs could be significantly correlated with enhanced serum IL-8. Furthermore, using stably reduced SPTAN1-expressing SW480, SW620 or HT-29 cell lines, the RAS

Indexed as

ButadienesColorectal NeoplasmsFluorouracilInterleukin-8NitrilesAgedAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorExtracellular Signal-Regulated MAP KinasesFemaleGene Expression Regulation, NeoplasticHT29 CellsHumansLeucovorinMaleMAP Kinase Signaling SystemButadienesExtracellular Signal-Regulated MAP KinasesFluorouracilInterleukin-8LeucovorinMLH1 protein, humanMutL Protein Homolog 1NitrilesOrganoplatinum CompoundsU 0126colorectal cancerepithelial–mesenchymal transitioninterleukin-8non-erythrocytic spectrin alpha IItumor microenvironment

Identifiers

PMID38891846
PMCPMC11172072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.